By Amith Chordia and John Barry.

Eli Lilly’s recent acquisition of Kelonia raised eyebrows, not because of what’s proven, but because of what isn’t.

At face value, the deal looks bold, even risky: a significant investment in a company with limited clinical validation and a still-emerging technology platform. But zoom out, and the logic becomes clearer. This isn’t just a bet on Kelonia. It’s a bet on the future architecture of cell therapy.

From Assets to Platforms

Lilly’s move only fully makes sense in context. Over the past few years, the company has been quietly assembling a portfolio of capabilities in in vivo genetic medicine:

• Orna Therapeutics – RNA-based in vivo CAR-T approaches
• Verve Therapeutics – in vivo gene editing
• Kelonia – lentiviral delivery for in vivo cell engineering

Taken together, this is not a collection of isolated bets. It is a coordinated build. Lilly appears to be constructing a modality-spanning platform, where different technological approaches can be deployed depending on the disease, setting, and therapeutic goal.

In that light, Kelonia fills less of a pipeline gap and more of a capability gap.

Why Kelonia and Why Now?

Among in vivo cell therapy players, Kelonia is arguably one of the more clinically advanced, particularly in lentiviral delivery. That matters in a space where proof of concept is still scarce.

But timing and competition likely played a role as well. With other pharma players such as Johnson and Johnson already circling the space, waiting comes with strategic risk. If in vivo CAR-T works, it has the potential to eliminate some of the biggest bottlenecks in current therapies, including manufacturing complexity and cost of goods.

From that perspective, paying a premium today may be less about overpaying for certainty and more about securing optionality in a high stakes race.

Hedging the Modality Question

One of the more interesting aspects of Lilly’s strategy is what it does not assume.

Rather than picking a single winning technology, Lilly is hedging across modalities:

• RNA-based delivery (Orna)
• Lentiviral delivery (Kelonia)

Both approaches aim to unlock in vivo cell therapy, but with different trade-offs.

RNA-based systems may offer advantages in safety and controllability, potentially enabling repeat dosing and making them attractive in settings like autoimmune disease, where tolerability and quality of life are paramount.

Lentiviral approaches, on the other hand, may offer greater persistence. This is an important feature in oncology, where durability of response is often critical and higher toxicity thresholds are more acceptable.

The implication is that the future may not be about which modality wins, but where each modality fits.

The Durability Question

If there is a single unresolved question hanging over the entire in vivo cell therapy field, it is durability.

Early data, including small studies like Kelonia’s BCMA targeting program showing deep responses without lymphodepletion, are promising but far from definitive. The key unknown is whether these responses will last.

This uncertainty reinforces the logic of Lilly’s multi platform approach. If durability proves challenging, technologies that enable repeat dosing such as RNA based systems may become more important. If strong persistence is achieved within relevant indications, approaches with better convenience (and potentially price) could dominate.

From Ex Vivo to In Vivo

Stepping back, the strategic direction is hard to miss.

Across the industry, there is a growing conviction that the future of cell therapy lies in vivo. The potential advantages are compelling: simplified logistics, lower cost of goods, broader accessibility, and the possibility of treating patients earlier in the disease course.

Lilly’s Kelonia acquisition does not prove that vision, but it does underscore belief in it.

And in a space where the science is still catching up to the ambition, belief backed by capital and capability building may be the most important signal of all.

Reach out to Amith and John to discuss these insights or your needs in this space.